22:35 , Jul 11, 2019 |  BC Innovations  |  Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins. Launched last September, the company is using an $82.8 million series A...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
16:41 , Jun 5, 2017 |  BC Extra  |  Clinical News

Zika virus hijacks neurodevelopmental protein to replicate

In a paper published in Science , University of Cambridge researchers show the Zika virus hijacks neurodevelopmental protein Musashi RNA-binding protein 1 (MSI1) in neural stem cells, increasing viral replication and preventing neural stem cell...
07:00 , Jun 23, 2016 |  BC Innovations  |  Translation in Brief

Musashi's dual duel

The Musashi genes were originally named for the samurai who fought with two swords because, when discovered in flies, their mutation created double-shafted bristles. Now, a pair of studies double down on the name, showing...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colon cancer Notch 3 (NOTCH3); Musashi RNA binding protein 1 (MSI1) In vitro and mouse studies suggest inhibiting NOTCH3 could help treat colon cancer. In...
07:00 , Aug 19, 2010 |  BC Innovations  |  Targets & Mechanisms

Leukemia takes it up a NOTCH

The Notch pathway has been linked to aggressive growth in a range of tumor types but had not previously been considered a prime target for myeloid leukemia therapies. Separate American teams now have identified two...